THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) The category of combination formulations referred to in the question would depend on the therapeutic use. The formulations required for National Health Programmes specified in Schedule-I of the DPCO, 1987 would be classified as Category I formulations while all other formulations would be treated as Category II. MAPE 100 per cent of the ex-factory cost has been allowed for all Category II formulations.

(c) No, Sir.

Revision of formulation prices

3751. SHRI JAGESH DESAI:
SHRI JASWANT SINGH:

Will the Minister of INDUSTRY be pleased to refer to the answer to the Unstarred Question 665 given in the Rajya Sabha on the 2nd May, 1988 and state:

(a) what are the approved prices of Rifampicin 600 mg, Rifampicin 450 mg. plus IMH, Electral, IMH and Vitamin B6 liquid under DPCO, 1979 and under DPCO, 1987;

(b) under what conditions the prices are revised by Government based on applications;

(c) who is responsible for exercising check on the fact that the prices of all the formulations based on a particular bulk drug are reduced simultaneously;

(d) what are the guidelines and criteria followed for revising the prices of formulations by the sub-committee of DPRC; and

(e) whether it is a fact that this committee is responsible to no-body and have taken inconsistent and ad hoc decisions?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Details of prices fixed under DPCO, 1979 are not readily available. Prices under DPCO, 1987 have been fixed for only one product referred to in the question as per details given below:

Name of the Formulation	Pack Size	Ceiling price (Rs.)
Rifampicin 450 mg	3's	9.00
+IMH 300 mg	4's	12.01
Capsules	10's	30.00

(b) and (d) Prices of Scheduled formulations are fixed/revised as per provisions of DPCO, 1987.

(c) Prices of formulations based on any particular bulk drug(s) are reduced by this Ministry *suo-moto* wherever considered necessary.

(d) Recommendations of the sub-committee of the DPRC are finally considered by this Ministry and modified suitably wherever necessary.

Intimating drug companies about DPEA arrears

3752. SHRI BEKAL UTSAHI: Will the Minister of INDUSTRY be pleased to refer to the answer to the Unstarred Question 662 given in the Rajya Sabha on the 2nd May, 1988 and state:

(a) when was the assessed amount communicated to each company and